NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation - sprookjes - yvandenbroek - TriplyDB

NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation

NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation

http://www.wikidata.org/entity/Q24653076

about

Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine t10c12 conjugated linoleic acid suppresses HER2 protein and enhances apoptosis in SKBr3 breast cancer cells: possible role of COX2.Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype.Glycogen synthase kinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma.Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase-independent cancer cell death.Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer.Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis.X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.The interaction between ER and NFκB in resistance to endocrine therapy.Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma Role of NF-κB as a Prognostic Marker in Breast Cancer : A Pilot Study in Indian Patients A new cross-talk between the aryl hydrocarbon receptor and RelB, a member of the NF-kappaB family Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways Emerging EGFR antagonists for breast cancer.Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells.Estrogen receptor α in cancer associated fibroblasts suppresses prostate cancer invasion via reducing CCL5, IL6 and macrophage infiltration in the tumor microenvironment.Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.Identification of frequent somatic mutations in inflammatory breast cancer.Antimetastatic effect of nobiletin through the down-regulation of CXC chemokine receptor type 4 and matrix metallopeptidase-9.Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.High-throughput profiling of tissue and tissue model microarrays: Combined transmitted light and 3-color fluorescence digital pathology.Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease The tumor microenvironment and inflammatory breast cancer.Redefining the role of peripheral LPS as a neuroinflammatory agent and evaluating the role of hydrogen sulphide through metformin intervention.Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.Molecular mechanisms of hormone resistance of breast cancer.

P2860

Q28554790-A40E4B47-5801-4C9E-A715-C0C875C702AC Q30862407-CE78A333-4F64-4640-B91D-C9EC768D5083 Q33317058-7CCD332F-7E0F-4DA1-B04F-27D48799F101 Q34130168-69F002E8-24B4-4873-B613-D49A63A284C7 Q34637826-B9714537-E102-481D-A534-153E301D9E92 Q35496324-F44ACB1C-F540-44FD-8263-7260A53856F3 Q35949760-86E44F1E-4DAF-4C94-A3F7-B22CFBBFAF9E Q36082731-82FA7A23-A985-4883-95C6-978BDD1E3635 Q36611440-EC017091-B138-47CF-8E78-12831157F804 Q36751784-F4D4D72A-3FCC-4790-B6C7-A4E4BECE6BF5 Q36924406-DCEF132C-06DD-44B3-AF99-302E0A804D18 Q37151107-340013EB-51FE-4790-AE91-32754373809B Q37165541-E90FFDB5-AE44-47B8-ACFF-69B16EA46FA2 Q37207403-1742A208-B089-451C-B031-1749C7A13EBF Q37686006-411F7909-242D-4D64-8CF8-2D0B8D936E81 Q38211951-5E29D8C1-416D-4941-A19B-BB4D96A126AC Q38706762-EA0E7F41-810D-4B1A-AC7C-AC05D5F299D5 Q38801346-4567011B-855F-4F7E-B7BE-8C8465250C81 Q38803734-91DE7E6C-AAEB-4164-BAAA-572FC26DCAB8 Q38938061-E48268C8-0543-49F9-A326-FE60DE998F25 Q39304192-3652E94F-26D5-4801-82C5-FFC4792CCFE4 Q39430345-6B12E36F-2897-4EE0-A550-967AF74964C0 Q39766695-A263A838-DC2B-4E4E-9E74-2275D8687D0D Q41136265-852CC697-0964-460A-AFC6-40E31873B103 Q41396244-8C7597B6-C90D-48EB-960F-6711CA04C1CF Q48589396-A5192F98-C4C9-46E2-9B1E-E5F5FEDD2877 Q49887925-6F188AFF-EFA0-414D-B2EE-D6B8D0D4DB56 Q53086084-77BAA1DD-2884-4055-90DA-249DF3BD58BC

P2860

NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation

http://www.wikidata.org/entity/Q24653076

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation

@ast

NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation

@en

NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation

@nl

type

label

NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation

@ast

NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation

@en

NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation

@nl

prefLabel

NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation

@ast

NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation

@en

NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation

@nl

P1433

Q24653076-22F7F790-4A6D-429B-866D-5CD8E0A8519C

P1476

Q24653076-7E1CFCF0-0545-47EA-93CC-1919D3C35748

P2093

Q24653076-202D39E0-1BE7-4F35-8F18-CFCAB26254B7

Q24653076-353D4373-BCC0-4F32-9713-70D7A560F8DE

Q24653076-9B5FA9D1-72A9-494B-8967-5EE8D3D1300D

Q24653076-B72B2135-06CE-4C48-BDAF-ED9C328936A1

Q24653076-D3F151C5-6AE4-4E60-A40F-311204D21565

Q24653076-DC906ED7-2BB3-443E-8858-558A3F3432E5

Q24653076-E0D1EB21-07D7-4840-B658-BA7A9FA22B1D

P2860

Q24653076-028FDC41-41C7-4F5C-BECC-263F079F14D2

Q24653076-07052FC0-E4DA-4C81-93DC-B962E42DFDE2

Q24653076-0D10B5B6-3551-4BE9-9E4E-5FD74B4133CF

Q24653076-11C7E2AF-BA61-40FD-A115-9C44C51E4F77

Q24653076-15D10B3A-1683-4BCD-A7F5-726A8281D0E9

Q24653076-1666FF45-AD77-4C4E-BDBF-C56508A679C1

Q24653076-1C96B0BB-81EA-4612-B1BC-8F8926E41126

Q24653076-232B76C6-5BEC-4C3F-B5D9-7EEDDA876353

Q24653076-24920CB9-EEED-466A-A6CB-91BFB8C9693C

Q24653076-2D6C1E13-C822-4FED-9085-AF8D0FBC809A

P2888

Q24653076-DD7769F4-6689-421D-94BC-2E12317E6ADE

P304

Q24653076-68FA1079-F674-4591-A568-FCD404D7C7BC

P31

Q24653076-DF5ADF25-C64F-44EA-A41A-40AD8DFF0DE5

P356

Q24653076-E7F6A33F-CFC6-4357-BAC6-7045BD9EA726

P407

Q24653076-233B70A8-B94E-41C9-B775-7659ED862325

P433

Q24653076-35C56B84-C975-4FD3-822D-89CCFEBC9DA2

P478

Q24653076-1C33455E-E9C4-4060-999E-8C5032F30D0C

P577

Q24653076-0C3E0352-43FB-48D3-B2D8-5617A3F35EDF

P5875

Q24653076-7B9EDB5B-C742-409B-A024-9DDC3E6446A5

P6179

Q24653076-E7249954-CD0E-4942-8599-64A23650391A

P698

Q24653076-CBA13D7C-EEBB-44DF-B641-C4A9FB8424F0

P921

Q24653076-7268D4D4-F465-43F1-9035-966972D681AC

Q24653076-CD55F2D1-7B01-4BF3-8F73-288ACFF22EE9

P932

Q24653076-A864F8DF-09DF-4815-A1EF-7E461DC51F75

P356

P1433

British Journal of Cancer

P1476

NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation

@en

P2093

E A Van Marck

http://www.w3.org/2001/XMLSchema#string

G G Van den Eynden

http://www.w3.org/2001/XMLSchema#string

I Van der Auwera

http://www.w3.org/2001/XMLSchema#string

L Y Dirix

http://www.w3.org/2001/XMLSchema#string

P B Vermeulen

http://www.w3.org/2001/XMLSchema#string

P van Dam

http://www.w3.org/2001/XMLSchema#string

S J Van Laere

http://www.w3.org/2001/XMLSchema#string

P2860

Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta

WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer

Update on inflammatory breast cancer

Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants.

Inflammatory breast cancer: relationship between growth factor signaling and motility in aggressive cancers

Gene expression signature of estrogen receptor alpha status in breast cancer

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Molecular portraits of human breast tumours

Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer

Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence

P2888

P304

659-69

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6603906

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6138353

http://www.w3.org/2001/XMLSchema#string

P6179

1047148376

http://www.w3.org/2001/XMLSchema#string

P698

17700572

http://www.w3.org/2001/XMLSchema#string

P921

P932

2360371

http://www.w3.org/2001/XMLSchema#string